Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Supplemental metolazone diuresis

PreclinicalSmall molecule

OOregon Health and Science University

Supplemental metolazone diuresis is one of 2 small molecule programs targeting Hypernatremia. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypernatremiaActive, not recruiting

HypernatremiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Hypernatremia

#DrugCompanyPhaseTrials

Supplemental metolazone diuresis

OOregon Health and Science University

Hypotonic

HHospital Civil de Guadalajara

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypernatremia1 trial

Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis

Withdrawn·OOregon Health and Science University·N/A·NCT01617798

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Supplemental metolazone diuresis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Supplemental metolazone diuresis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Supplemental metolazone diuresis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oregon Health and Science University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOregon Health and Science University

Related News